Shares of Juno Therapeutics Inc (NASDAQ:JUNO) traded down 0% during mid-day trading on Thursday after Maxim Group lowered their price target on the stock from $50.00 to $34.00. Maxim Group currently has a buy rating on the stock. Juno Therapeutics traded as low as $19.41 and last traded at $22.56, with a volume of 17,580,347 shares changing hands. The stock had previously closed at $22.56.

Several other equities analysts also recently commented on JUNO. FBR & Co set a $61.00 price target on shares of Juno Therapeutics and gave the company a “buy” rating in a report on Friday, August 5th. Standpoint Research assumed coverage on shares of Juno Therapeutics in a report on Thursday, August 25th. They set a “buy” rating and a $47.00 price target on the stock. BTIG Research upgraded shares of Juno Therapeutics from a “sell” rating to a “neutral” rating in a report on Thursday, November 3rd. Zacks Investment Research downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 5th. Finally, Vetr downgraded shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 price target on the stock. in a report on Tuesday, August 16th. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $43.13.

In related news, CEO Hans Edgar Bishop sold 84,035 shares of the stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $30.28, for a total transaction of $2,544,579.80. Following the completion of the sale, the chief executive officer now owns 2,518,537 shares of the company’s stock, valued at $76,261,300.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert Azelby sold 12,921 shares of the stock in a transaction that occurred on Thursday, November 10th. The shares were sold at an average price of $24.14, for a total transaction of $311,912.94. Following the sale, the executive vice president now directly owns 48,640 shares of the company’s stock, valued at approximately $1,174,169.60. The disclosure for this sale can be found here.

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Juno Therapeutics by 14.8% in the second quarter. Vanguard Group Inc. now owns 5,471,650 shares of the biopharmaceutical company’s stock worth $210,331,000 after buying an additional 707,140 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Juno Therapeutics by 40.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,663,180 shares of the biopharmaceutical company’s stock worth $63,933,000 after buying an additional 475,709 shares during the last quarter. Lord Abbett & CO. LLC boosted its stake in Juno Therapeutics by 222.9% in the second quarter. Lord Abbett & CO. LLC now owns 688,876 shares of the biopharmaceutical company’s stock worth $26,480,000 after buying an additional 475,553 shares during the last quarter. BlackRock Fund Advisors boosted its stake in Juno Therapeutics by 29.5% in the second quarter. BlackRock Fund Advisors now owns 1,964,403 shares of the biopharmaceutical company’s stock worth $75,512,000 after buying an additional 446,978 shares during the last quarter. Finally, State Street Corp boosted its stake in Juno Therapeutics by 36.1% in the second quarter. State Street Corp now owns 1,658,792 shares of the biopharmaceutical company’s stock worth $63,764,000 after buying an additional 440,324 shares during the last quarter.

The company’s 50 day moving average price is $27.75 and its 200-day moving average price is $33.02. The stock’s market capitalization is $2.31 billion.

Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $20.80 million for the quarter, compared to the consensus estimate of $10.98 million. During the same quarter in the previous year, the business earned ($0.26) earnings per share. Juno Therapeutics’s revenue for the quarter was up 1200.0% compared to the same quarter last year. Equities analysts forecast that Juno Therapeutics Inc will post ($2.54) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/24/juno-therapeutics-inc-juno-stock-price-down-0-after-analyst-downgrade.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

5 Day Chart for NASDAQ:JUNO

Receive News & Stock Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related stocks with our FREE daily email newsletter.